BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Parcell Laboratories Chief Scientific Officer Dr. Colin White To Speak On Innovative Regenerative Medicine Technologies At Upcoming Conferences In San Diego And New York City


2/14/2014 9:28:24 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NATICK, MA--(Marketwired - February 13, 2014) -

Dr. Colin White, newly-appointed chief scientific officer at Parcell Laboratories, will speak on the scientific foundation for the company's patented ELA® cell platform technology and on the benefits it offers to allogeneic cell-based therapies at two conferences next week. He will share his thoughts on the first-mover advantages surrounding allograft cell-based products at the New York Stem Cell Summit '14 on February 18. At the Global Technology Community's Cell & Gene Therapy Conference in San Diego on February 20, Dr. White will lecture on the discovery, isolation and characterization of the ELA cell, describing how ELA cells represent a novel source of stem cells for the potential treatment of numerous diseases.

"Parcell Labs will be unveiling its platform technology, backed by clinical data that supports our work, to the world's scientific community at the Global Technology Community's Cell & Gene Therapy Conference," said Dr. White. "It will be the first opportunity we've had to share our research and development efforts with the world. At the New York Stem Cell Summit, we will showcase our first-mover perspective on the regulatory pathway of cell-based therapies, the necessities of and hard work behind delivering a robust quality system, and our clinical data to date."

At the New York Stem Cell Summit, Dr. White will join a panel of industry professionals to discuss the first-mover advantage of allograft cell-based products, which have already generated more than $200 million in hospital purchases in 2013. As first-movers, Dr. White and the other panelists will discuss the manufacturing processes and regulatory pathways for cell-based products, as well as their safety, efficacy and the physician response.

Dr. White's presentation at the Global Technology Community's Cell & Gene Therapy Conference will include a detailed report on the discovery, isolation and characterization of a novel population of synovial fluid-derived adult stem cells, which Parcell Labs has termed Early Lineage Adult (ELA) stem cells. In vitro studies reveal that ELA cells differentiate into tissues of ectodermal, mesodermal, and endodermal origins, and in vivo studies demonstrate that ELA cells harbor a significant osteogenic differentiation capacity. Clinically, an ELA cell-based therapy has been developed and used commercially in approximately 3,500 surgical procedures for spinal fusion, and a retrospective chart review of treated patients revealed promising results, with detectable fusion as early as six months post-surgery and no attributable adverse events. Parcell Labs' data indicate that ELA cells likely represent a novel source of stem cells for the potential treatment of numerous diseases.

About Parcell Laboratories

Parcell Laboratories, Inc., founded in 2008, develops novel therapeutics based on its patented adult stem cell platform technology, the ELA® cell. The ELA cell was discovered by scientists affiliated with the Brigham and Women's Hospital and Harvard Medical School, who demonstrated the vast potential of the technology in regenerative medicine. ELA cells are found in various tissues throughout the body and are characterized by a specific surface marker profile that set them apart from other adult stem cells. Based in Natick, Mass., the company's state-of-the-art research, processing, storage and fulfillment facilities set the stage for the future of adult stem cells and regenerative medicine. For more information, visit www.parcelllabs.com. Parcell Laboratories is a member of the Parcell Group of companies, which also includes CellCure Trust, LLC and Cellogx, LLC.


Todd Van Hoosear or Ruth Bazinet
HB Agency
Parcell@hbagency.com
(781) 893-0053



Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES